Navigation Links
Drug development venture links translational research, business to launch new therapeutics
Date:6/12/2013

Emory University today announced an innovative new public-private drug development enterprise that will transition scientific discoveries more rapidly and efficiently from university laboratories into the marketplace. The new venture is expected to provide global solutions to address worldwide drug development and commercialization needs.

Drug Innovation Ventures at Emory, LLC (DRIVE) is a not-for-profit company separate from, but wholly owned by Emory. DRIVE will expand the capabilities of traditional academic drug research by combining the expertise of Emory scientists and their unprecedented record of innovation and success in drug discovery with a world-renowned development, business and management team of industry leaders.

DRIVE will provide the financial, business, project management and regulatory expertise to effectively move drugs through lead optimization and pre-clinical testing a stage of drug development often termed the "Valley of Death" -- and into proof-of-concept clinical trials. Technologies with added value can then be out-licensed to pharmaceutical and biotechnology companies, partnered with foundations or government entities, or spun-out into newly formed companies financed by venture capital firms.

DRIVE is the first initiative to be established within Emory Innovations, Inc., a newly created 501(c)(3) corporation that will serve as the home for innovative new enterprises, with the mission of supporting and enhancing the goals of Emory University.

"Emory's unprecedented record of success in drug discovery creates an excellent opportunity to pursue an innovative new venture for translating scientific discoveries into therapeutics for unmet medical needs," says Emory President James Wagner. "This financially self-sustaining public-private enterprise fits within Emory's vision of working collaboratively for positive transformation in the world through discoveries that are of global benefit."

DRIVE will function as the "industrial partner" of the Emory Institute for Drug Development (EIDD). Established in 2009, EIDD has an experienced drug development team, equipment and laboratory facilities necessary to transition drug discovery efforts into preclinical and clinical molecules.

"The traditional pharmaceutical research and development operating model is no longer sustainable," says Dennis Liotta, PhD, founder of the Emory Institute for Drug Development (EIDD) and co-inventor of multiple approved drugs. "The marked decrease in the development of new therapeutics is having a uniformly negative effect on global health and threatens life expectancy, quality of life, economic development and national security. Emory's new public-private enterprise is a bold new approach that can help solve this problem."

DRIVE will finance its initial efforts with $10 million in funding received from the monetization of royalties associated with HIV drug emtricitabine (Emtriva) and additional funding from governmental agencies, partner institutions, as well as contributions from philanthropic and investment groups. The new enterprise will also invest Emory's share of financial gains from technology transfer into research, education and patient care.


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory Health Sciences
Source:Eurekalert

Related biology news :

1. Dads life stress exposure can affect offspring brain development, Penn Study finds
2. Stem cells reach standard for use in drug development
3. DigitalPersona Announces U.are.U Software Development Kit (SDK) for Android Applications
4. Researchers discover how brain circuits can become miswired during development
5. Carnegie Mellon neuroscientists discover new phase of synaptic development
6. Evonik Industries Selects OPX Biotechnologies for Joint Development of Bio-Based Chemicals
7. Turning human stem cells into brain cells sheds light on neural development
8. Turtle genome analysis sheds light on the development and evolution of turtle-specific body plan
9. Developmental neurobiology: How the brain folds to fit
10. Particular DNA changes linked with prostate cancer development and lethality
11. Development of novel therapies for endothelial damage may heal atherosclerotic plaques
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology: